Results for this period
First quarter1 April 2026 to 30 June 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Although sales of overseas pharmaceuticals declined, revenue increased 1.2% year on year due to growth in the LAL business and other operations. An operating loss was recorded due to higher manufacturing costs, while ordinary income was recorded due to the sale of investment securities and other factors. A quarterly net loss attributable to owners of the parent was recorded due to higher tax expenses.
No applicable matters.
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 June 2026 |
| Net Sales | ¥8,833 million (YoY +1.2%) |
| Operating profit | ¥-943 million |
| Ordinary income | ¥108 million |
| Profit attributable to owners of the parent | ¥-11 million |
| Net income per share | ¥(0.21) |
| Equity ratio | End of the current fiscal period 87.8 / End of previous period 87.2 |
| Total assets | ¥84,490 million |
| Net assets | ¥74,189 million |
| Full-year earnings forecast | Net Sales ¥41,850 million (YoY +14.2%) / Operating profit ¥2,050 million / Ordinary income ¥4,200 million (YoY +150.0%) / Net income ¥2,250 million (YoY +52.7%) |
| Annual Dividend Forecast | ¥30 → ¥30（0.0%） |
| Segment revenue | Pharmaceuticals ¥5,448 million (YoY -7.7%), LAL ¥3,385 million (YoY +19.7%) |
| Segment profit | Pharmaceuticals ¥-1,167 million, LAL ¥223 million |
| Depreciation and amortization | ¥560 million |
| Impairment loss | None (impairment loss on fixed assets) |
| Breakdown of extraordinary income (loss) | None (no extraordinary income or extraordinary loss reported) |
| Disclosure regarding the going concern assumption | No applicable matters. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New 0 / Excluded 0 / Company name Not disclosed |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | None (対象者：Not disclosed) |
| Issued Shares at Period-End | 56,814,093 Shares |
| Treasury Shares at Period-End | 2,211,399 Shares |
| Factors Behind Changes in Business Performance | Although sales of overseas pharmaceuticals declined, revenue increased 1.2% year on year due to growth in the LAL business and other operations. An operating loss was recorded due to higher manufacturing costs, while ordinary income was recorded due to the sale of investment securities and other factors. A quarterly net loss attributable to owners of the parent was recorded due to higher tax expenses. |
Items this document does not state (11)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Although sales of overseas pharmaceuticals declined, revenue increased due to growth in the LAL business and other operations. The operating loss was attributable to higher manufacturing costs, ordinary income to the sale of investment securities and other factors, and the quarterly net loss attributable to owners of the parent to higher tax expenses.